Study guide

2.1 Organelles, Cytoskeleton & Membrane Transport

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

2.1 Organelles, Cytoskeleton & Membrane Transport

Key Takeaways Explain This Topic AI

Intermediate filament immunohistochemistry distinguishes tumour lineage: cytokeratin for carcinoma, vimentin for sarcoma, desmin for muscle, GFAP for glioma and S100 for melanoma.

CFTR is an ATP-binding cassette chloride channel; class II mutations such as F508del cause misfolding and proteasomal degradation rather than absent transcription.

Primary ciliary dyskinesia produces bronchiectasis, sinusitis and situs inversus through defective dynein arms in motile cilia.

Last updated: September 2026

Note

MRCP Part 1 Blueprint Focus : The cellular and molecular biology syllabus tests the mechanistic basis of systemic disease and targeted pharmacotherapy. Candidates are frequently tested on organelle pathology (e.g., lysosomal and peroxisomal storage defects), intermediate filament immunohistochemistry, cell cycle checkpoint kinetics (p53 and Rb tumor suppressor pathways), intrinsic vs. extrinsic apoptosis, and second messenger cascades.

Organelle Function, Trafficking & Pathological Correlates

Eukaryotic cells rely on compartmentalized organelles to separate biosynthetic, metabolic, and degradative processes. Structural or enzymatic failure within these compartments produces characteristic clinical syndromes.

Endoplasmic Reticulum and Golgi Apparatus

Rough Endoplasmic Reticulum (RER) : Site of synthesis of membrane-bound, lysosomal, and secretory proteins. Proteins enter the RER lumen via signal peptides. Molecular chaperones (BiP, calreticulin, calnexin) ensure correct tertiary folding.

Unfolded Protein Response (UPR) : Accumulation of misfolded proteins triggers endoplasmic reticulum stress, activating sensor proteins (PERK, IRE1, ATF6) that inhibit general translation while upregulating chaperone synthesis. Prolonged ER stress induces apoptosis via CHOP-mediated Bim activation.

Smooth Endoplasmic Reticulum (SER) : Devoid of ribosomes; executes lipid and steroid hormone synthesis (abundant in adrenal cortex and gonads), glycogen catabolism, and cytochrome P450-mediated drug detoxification (in hepatocytes). The sarcoplasmic reticulum of myocytes acts as a dedicated intracellular calcium store.

Golgi Apparatus : Coordinates post-translational modifications, sorting, and packaging. Executes N-linked oligosaccharide modification, O-linked glycosylation, and sulfation.

Mannose-6-Phosphate (M6P) Tagging : Acid hydrolases destined for lysosomes receive an M6P tag in the cis -Golgi via phosphotransferase (N-acetylglucosaminyl-1-phosphotransferase). In I-cell disease (mucolipidosis type II) , deficiency of this phosphotransferase leaves lysosomal enzymes untagged; they are erroneously secreted into extracellular fluid. Lysosomes become engorged with undegraded substrates, producing coarse facial features, skeletal dysostosis multiplex, severe psychomotor retardation, and early childhood mortality.

Peroxisomes

Peroxisomes contain oxidative enzymes (catalase, urate oxidase) that catabolise very long chain fatty acids (VLCFAs, >C22) via beta-oxidation, branched-chain fatty acids (phytanic acid) via alpha-oxidation, and synthesize plasmalogens (essential myelin phospholipids).

Zellweger Syndrome : Autosomal recessive mutation in PEX genes encoding peroxin proteins essential for peroxisome assembly. Patients present in the neonatal period with severe hypotonia ("floppy infant"), craniofacial dysmorphism (high forehead, wide fontanelles), hepatomegaly, and death within the first year.

Refsum Disease : Autosomal recessive deficiency of phytanoyl-CoA hydroxylase , blocking alpha-oxidation of phytanic acid. Clinical triad: cerebellar ataxia, retinitis pigmentosa, and peripheral sensorimotor neuropathy, accompanied by ichthyosis and sensorineural hearing loss. Treatment requires dietary restriction of dairy products and ruminant meats.

X-Linked Adrenoleukodystrophy (X-ALD) : Inactivating mutation in the ABCD1 peroxisomal transporter gene, preventing VLCFA entry into peroxisomes. VLCFAs accumulate in the cerebral white matter and adrenal cortex, causing progressive neurocognitive decline, spastic quadriparesis, and primary adrenal insufficiency (Addisonian crisis) in young boys.

Cytoskeletal Architecture & Diagnostic Immunohistochemistry

The eukaryotic cytoskeleton comprises microfilaments, intermediate filaments, and microtubules, maintaining spatial organization, cell motility, and intracellular transport.

Filament Class Structural Subunits Primary Functions High-Yield Pathological / Clinical Correlate

Microfilaments G-actin monomers polymerising to F-actin Cell locomotion, cytokinesis (cleavage furrow), microvilli core Cytochalasin (blocks polymerisation); Phalloidin (stabilises actin, prevents depolymerisation)

Intermediate Filaments Tissue-specific fibrous proteins (10 nm) Tensile strength, structural scaffolding Tumor classification via immunohistochemistry (IHC) in metastatic undifferentiated malignancies

Microtubules Alpha- and beta-tubulin heterodimers (25 nm) Chromosome segregation (mitotic spindle), ciliary motility, axonal transport Primary ciliary dyskinesia (Kartagener syndrome); antimitotic chemotherapy targets

Immunohistochemical Utility of Intermediate Filaments

When pathologists evaluate an undifferentiated metastatic carcinoma, sarcoma, or lymphoma, intermediate filament immunohistochemistry defines the tissue of origin:

Cytokeratin : Epithelial cells; positive in carcinomas.

Vimentin : Mesenchymal cells; positive in sarcomas, renal cell carcinoma, and endometrial carcinoma.

Desmin : Skeletal, smooth, and cardiac muscle; positive in rhabdomyosarcomas and leiomyosarcomas.

Glial Fibrillary Acidic Protein (GFAP) : Astrocytes, oligodendrocytes, ependymal cells; positive in astrocytomas and glioblastoma multiforme.

Neurofilaments : Neuronal axons and dendrites; positive in neuroblastoma, pheochromocytoma, and ganglioneuroma.

Microtubule Dynamics and Molecular Motor Proteins

Microtubules are polar polymers with dynamic plus ends (growing toward the cell periphery) and minus ends (anchored at the centrosome/microtubule-organizing center).

Kinesin : ATP-dependent motor protein moving anterograde (minus-to-plus, centrosome to cell periphery; transports vesicles and organelles toward the synaptic terminal).

Dynein : ATP-dependent motor protein moving retrograde (plus-to-minus, cell periphery to centrosome; transports endosomes, neurotropic viruses such as Rabies and HSV, and retrograde signals).

Primary Ciliary Dyskinesia (Kartagener Syndrome) : Autosomal recessive defect in ciliary dynein arms , immobilizing respiratory cilia and sperm flagella. Classic triad: bronchiectasis , chronic sinusitis , and situs inversus (Kartagener syndrome = PCD with situs inversus due to absent embryonic nodal ciliary rotation), plus male subfertility.

Pharmacological Modulators : Colchicine binds tubulin dimers to inhibit polymerisation (blocking neutrophil extravasation in acute gout). Vinca alkaloids (vincristine, vinblastine) arrest cells in metaphase by disrupting spindle assembly. Taxanes (paclitaxel, docetaxel) hyperstabilize microtubules, preventing depolymerisation and blocking anaphase completion.

Membrane Transport Systems & Channelopathies

Biological membranes exhibit selective permeability maintained by specialized transport proteins. Membrane Transport Systems

  • ├── Passive Transport
  • │ ├── Simple Diffusion (lipophilic molecules: O2, CO2, steroids)
  • │ └── Facilitated Diffusion (GLUT transporters, resting ion channels)
  • └── Active Transport
  • ├── Primary Active Transport (direct ATP hydrolysis: Na+/K+ ATPase, SERCA, H+/K+ ATPase)
  • └── Secondary Active Transport (uses electrochemical gradient created by primary transport)
  • ├── Symport / Cotransport (SGLT1/2, Na+-K+-2Cl- cotransporter / NKCC2)
  • └── Antiport / Exchanger (Na+/Ca2+ exchanger / NCX, Na+/H+ exchanger / NHE1)
  • Primary vs. Secondary Active Transport

Na+/K+ ATPase : Primary active, electrogenic antiporter. Hydrolyses one ATP molecule to pump 3 Na+ out of the cell and 2 K+ into the cell against steep concentration gradients. Phosphorylated state (E2) binds cardiac glycosides (digoxin), which competitively block extracellular K+ binding, raising intracellular Na+. High intracellular Na+ reduces the driving force for the Na+/Ca2+ exchanger (NCX), elevating cytosolic Ca2+ to increase myocardial contractility.

Sodium-Glucose Cotransporter 2 (SGLT2) : Secondary active symporter located in the S1 segment of the renal proximal convoluted tubule. Couples the downhill reabsorption of Na+ to the uphill reabsorption of glucose. Selectively inhibited by gliflozins (dapagliflozin, empagliflozin), promoting glycosuria, osmotic diuresis, blood pressure reduction, and nephroprotection.

ABC Transporters & CFTR Pathophysiology

The ATP-Binding Cassette (ABC) transporter superfamily utilizes ATP hydrolysis to translocate substrates across lipid bilayers.

Multidrug Resistance Protein 1 (MDR1 / P-glycoprotein) : Overexpressed on malignant cells; actively extrudes hydrophobic chemotherapeutic agents (doxorubicin, etoposide, vincristine) from the cytoplasm, producing chemoresistance.

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) : A unique ABC transporter that functions as an ATP-gated, cAMP-regulated chloride channel across epithelial apical membranes. CFTR also tonically inhibits the epithelial sodium channel (ENaC) in respiratory and intestinal epithelia, while activating ENaC in sweat glands.

Mutation Class Molecular Mechanism Classic Genotype Clinical Phenotype

Class I Defective synthesis (premature stop codon / frameshift) G542X, W1282X Severe; complete absence of CFTR protein

Class II Defective processing & trafficking (ER-associated degradation) F508del (~70% of alleles) Severe; failure of folded protein to reach apical membrane

Class III Defective channel gating (normal membrane density, closed channel) G551D Severe; responds dramatically to potentiator ivacaftor

Class IV Defective conductance (pore constriction, reduced Cl- flow) R117H Mild/variable; residual pancreatic sufficiency common

  • Class V Reduced synthesis (splicing defect, reduced normal transcripts) A455E Mild; milder pulmonary phenotype
  • Class VI Reduced membrane stability (accelerated endocytosis/turnover) N287Y Moderate/severe phenotype

Important

The F508del Mutation : Deletion of 3 base pairs (CTT) results in loss of a single phenylalanine residue at position 508. This causes protein misfolding in the rough endoplasmic reticulum. Chaperones detect the abnormal conformation, targeting the channel for polyubiquitination and degradation by the 26S proteasome . As a result, virtually zero functional CFTR reaches the plasma membrane.

Aquaporins & Ion Channelopathies

Aquaporin-2 (AQP2) : Expressed in the apical membrane of principal cells in the renal medullary collecting duct. Under unstimulated conditions, AQP2 is stored in intracellular endosomes. Vasopressin binds basolateral V2 receptors , elevating cAMP via Gs, which triggers protein kinase A (PKA) to phosphorylate AQP2 and mobilize it to the apical plasma membrane, concentrating urine. Inactivating mutations in AVPR2 (X-linked) or AQP2 (autosomal) cause congenital nephrogenic diabetes insipidus .

Ryanodine Receptor 1 (RYR1) : Calcium-release channel on the sarcoplasmic reticulum membrane of skeletal myocytes. Autosomal dominant gain-of-function mutations cause malignant hyperthermia . Exposure to volatile halogenated anaesthetics (halothane, isoflurane) or depolarising muscle relaxants (suxamethonium) triggers uncontrolled sarcoplasmic reticulum Ca2+ release, causing sustained muscular rigidity, hypermetabolism, hyperthermia, rhabdomyolysis, and life-threatening lactic/respiratory acidosis. Treated immediately with dantrolene , which blocks the RYR1 channel.